NFL BIOSCIENCES
NFL Biosciences is a biotech which develops botanical drugs for the treatment of dependencies and addictions.
NFL BIOSCIENCES
Industry:
Biotechnology Medical Pharmaceutical
Address:
Castelnau-le-lez, Languedoc-Roussillon, France
Country:
France
Website Url:
http://www.nflbiosciences.com
Status:
Active
Contact:
+33.4.11.93.76.67
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Euro Google GStatic Google Static Content Google Cloud
Similar Organizations
Apex Biosolution
Apex Biosolution is a laboratory that helps in controlling microbiological risk more generally related to living organisms & microorganisms.
Aptarion biotech
Aptarion biotech is a developer Biostable L-Aptamers for the treatment Of Life-Threatening diseases And for Biosensors.
NeuroNova
NeuroNova is develops drug targets and candidates that demonstrate potential in the treatment of neurodegenerative diseases.
Panoptes
Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases.
VitaLeech Bioscience
VitaLeech Bioscience develops a recombinant enzyme for the treatment of periodontitis, a form of inflammation of the gum.
Stock Details
Official Site Inspections
http://www.nflbiosciences.com Semrush global rank: 4.85 M Semrush visits lastest month: 1.83 K
- Host name: h2web278.infomaniak.ch
- IP address: 84.16.76.225
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "NFL Biosciences"
Home - NFL Biosciences
NFL Biosciences develops botanical medicines for the treatment of addictions, with the goal of eventually partnering them with pharmaceutical companiesSee details»
Accueil - NFL Biosciences
NFL Biosciences développe des médicaments botaniques pour le traitement des addictions avec l’objectif de les licencier à des laboratoires pharmaceutiquesSee details»
Management Team - NFL Biosciences
Dr. Ignacio Faus joined NFL Biosciences in 2019 as an investor, then the management team in early 2021 as a director and CEO of NFL Biosciences. In February 2023 he was appointed …See details»
NFL Biosciences - Crunchbase Company Profile & Funding
NFL Biosciences is a biotech which develops botanical drugs for the treatment of dependencies and addictions. NFL Biosciences may be growing as it has successfully transitioned to the …See details»
NFL BIOSCIENCES - LinkedIn
NFL BIOSCIENCES clinically develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. It is delivered via two simple...See details»
Changes in the governance of NFL Biosciences - GlobeNewswire
Feb 27, 2023 · NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' …See details»
NFL Biosciences: 2021 full-year business and earnings update
Mar 28, 2022 · NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company that is developing botanical drugs for the treatment of addictions, …See details»
NFL Biosciences: 2021 full-year business and earnings
Mar 28, 2022 · NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company that is developing botanical drugs for the treatment of addictions, …See details»
NFL BIOSCIENCES : RESULTS OF THE COMBINED GENERAL …
Jun 28, 2023 · Details of voting and attendance are available on the company’s website, page “Shareholders General Meeting”: https://www.nflbiosciences.com.See details»
NFL BIOSCIENCES Initial Public offering on Euronext Growth
May 7, 2021 · NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents.See details»
NFL BIOSCIENCES: agreement signed with Diverchim to …
Nov 17, 2021 · NFL Biosciences SA, a biopharmaceutical company that is developing botanical drugs for the treatment of addictions, and Diverchim, a French market leader for the GMP …See details»
Mission - NFL Biosciences
Developing botanical medicines for the treatment of addiction. Botanical medicines, because of their natural origin, their often superior safety profiles to synthetic drugs, their versatility in …See details»
NFL BIOSCIENCES: agreement signed with Diverchim to
Nov 17, 2021 · NFL Biosciences SA, a biopharmaceutical company that is developing botanical drugs for the treatment of addictions, and Diverchim, a French market leader for the GMP …See details»
Press Releases - NFL Biosciences
Sep 9, 2024 · NFL BIOSCIENCES, a company committed to the fight against tobacco smoking, presents its clinical devlopment advances to help smokers quit (french only) 2023 first-half …See details»
NFL BIOSCIENCES: 2021 half-year financial and business report
Oct 4, 2021 · recruiting experienced experts to further strengthen its organization; launching the NFL-201 and NFL-301 programs, for the treatment of cannabis addiction and the reduction of …See details»
NFL Biosciences: 2022 first-half business and earnings - Yahoo …
Oct 25, 2022 · NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company that is developing botanical drugs for the treatment of addictions, …See details»
NFL Biosciences: 2021 half-year financial and business report
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company that is developing botanical drugs for the treatment of addictions, is releasing its …See details»
ALNFL Stock Price Quote - Morningstar
6 days ago · NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is …See details»
Nfl Biosciences Raises €5.0m Following Its Successful
Jul 5, 2021 · NFL Biosciences SA, a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing the success of its initial public offering on Euronext …See details»
Nfl Biosciences Raises €5.0m Following Its Successful Initial Public ...
Jul 5, 2021 · NFL Biosciences SA, a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing the success of its initial public offering on Euronext …See details»